tradingkey.logo

BRIEF-Verastem Oncology Announces FDA Acceptance And Priority Review Of New Drug Application For Avutometinib In Combination With Defactinib For The Treatment Of Recurrent Kras Mutant Low-Grade Serous Ovarian Cancer

ReutersDec 30, 2024 9:35 PM

- Verastem Inc VSTM.O:

  • VERASTEM ONCOLOGY ANNOUNCES FDA ACCEPTANCE AND PRIORITY REVIEW OF NEW DRUG APPLICATION FOR AVUTOMETINIB IN COMBINATION WITH DEFACTINIB FOR THE TREATMENT OF RECURRENT KRAS MUTANT LOW-GRADE SEROUS OVARIAN CANCER

  • VERASTEM INC - PDUFA TARGET ACTION DATE SET FOR JUNE 30, 2025

Source text: ID:nBwBJ6h5a

Further company coverage: VSTM.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI